KVUE

The defining fact in this filing isn't a number — it's the pending merger with Kimberly-Clark (K-C) that dominates the 10-K risk factors. KVUE holders are slated to receive K-C stock at an exchange ratio that is 'fixed and will not be adjusted,' so the value of what they get floats entirely with K-C's share price, and they will end up with 'a significantly reduced ownership and voting interest in the combined company.' At $18.12 the stock trades as a deal proxy, not on its own fundamentals; standalone valuation takes a back seat to deal completion, regulatory approval, integration, and the arbitrage spread.

The underlying business is good but stagnant. Revenue has gone $15.1B (FY2022) → $15.4B → $15.5B (FY2024) → $15.1B (FY2025, -2.1%) — essentially no growth in four years against 'intense competition, including from… private-label brands.' The iconic portfolio (Tylenol, Listerine, Neutrogena, BAND-AID, Nicorette, Zyrtec) still throws off a 58.1% gross margin and $2.20B of operating cash flow (+24.2%), and FY2025 profit rebounded sharply off the FY2024 trough: net income +42.7% to $1.47B, operating income +31.1%, diluted EPS $0.76 (+40.7%). But that is a recovery to a level still well below FY2022's $2.08B, not durable growth.